Page 39 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Role of common CXC chemokines in NAFLD

83. Knudsen C, Neyrinck AM, Leyrolle Q, et al. Hepatoprotective doi: 10.1007/s12072-016-9773-y
effects of indole, a gut microbial metabolite, in leptin- 87. Konishi H, Shirabe K, Nakagawara H, et al. Suppression
deficient obese mice. J Nutr. 2021;151(6):1507-1516.
of silent information regulator 1 activity in noncancerous
doi: 10.1093/jn/nxab032 tissues of hepatocellular carcinoma: Possible association
with non-B non-C hepatitis pathogenesis. Cancer Sci.
84. Jung JW, Wang F, Turk A, et al. Zaluzanin c alleviates
inflammation and lipid accumulation in kupffer cells and 2015;106(5):542-549.
hepatocytes by regulating mitochondrial ROS. Molecules. doi: 10.1111/cas.12653
2023;28(22):7484.
88. Alchera E, Rolla S, Imarisio C, et al. Adenosine A2a
doi: 10.3390/molecules28227484 receptor stimulation blocks development of nonalcoholic
steatohepatitis in mice by multilevel inhibition of signals
85. Tomita K, Kabashima A, Freeman BL, Bronk SF, Hirsova P,
Ibrahim SH. Mixed lineage kinase 3 mediates the induction of that cause immunolipotoxicity. Transl Res. 2017;182:75-87.
CXCL10 by a STAT1-dependent mechanism during hepatocyte doi: 10.1016/j.trsl.2016.11.009
lipotoxicity. J Cell Biochem. 2017;118(10):3249-3259.
89. Moragrega AB, Gruevska A, Fuster-Martínez I, et al. Anti-
doi: 10.1002/jcb.25973 inflammatory and immunomodulating effects of rilpivirine:
Relevance for the therapeutics of chronic liver disease.
86. Wada N, Takaki A, Ikeda F, et al. Serum-inducible protein
(IP)-10 is a disease progression-related marker for non- Biomed Pharmacother. 2023;167:115537.
alcoholic fatty liver disease. Hepatol Int. 2017;11(1):115-124. doi: 10.1016/j.biopha.2023.115537

Volume 9 Issue 3 (2025) 31 doi: 10.36922/ejmo.8383